Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.44 |
| ▸ | CTSD | P07339 | 7/20 | 0.44 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284558 | 1.00 | BACE1 (0.44) | BACE1CTSDRPS6KA2TP53POLB | |
| SCHEMBL2283110 | 0.91 | BACE1 (0.40) | BACE1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL2283122 | 0.91 | BACE1 (0.40) | BACE1CTSDMEN1KMT2AALDH1A1 | |
| SCHEMBL2282028 | 0.87 | BACE1 (0.41) | BACE1CTSDEGFR | |
| SCHEMBL2282020 | 0.87 | BACE1 (0.41) | BACE1CTSDEGFR | |
| SCHEMBL2279753 | 0.84 | BACE1 (0.47) | BACE1CTSDPOLBMAPTEGFR | |
| SCHEMBL2280139 | 0.84 | BACE1 (0.41) | BACE1CTSD | |
| SCHEMBL2280143 | 0.84 | BACE1 (0.41) | BACE1CTSD | |
| SCHEMBL7871291 | 0.83 | BACE1 (0.41) | BACE1CTSD | |
| SCHEMBL2287944 | 0.83 | BACE1 (0.39) | BACE1CTSDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245019-B1 | 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 721/4885RPS6KA2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.